One is to target the GSDME–YBX1–mucin pathway to deprive PDAC cells of their resistance to enzymatic digestion; another is to motivate the pore-forming activity of GSDME to trigger tumour cell pyroptosis and to activate antitumour immune responses. This evidence concerns the gene GSDME and neoplasm.